Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Now Has Problems At Its Dialysis Center In Bessemer, Alabama

Fresenius, the maker of the recalled dialysis drugs GranuFlo and NaturaLyte, is back in the news because its Bessemer, Alabama dialysis center has been closed due to two deaths and five hospitalizations of dialysis patients last month.

Consumer injury attorney Michael J. Evans announced today that he and two other law firms have launched a new website dedicated to providing information and offering legal assistance to people with potential claims caused by dialysis drugs, such as GranuFlo and NaturaLyte, or other dialysis malfeasance. The website is

“My litigation partners and I decided it was time to begin offering legal services to people who may have been injured by the recalled dialysis drugs GranuFlo and NaturaLyte, or who may have suffered injuries due to some other form of negligent conduct by the company performing dialysis,” said Evans.GranuFlo & NaturaLyte Dialysis Drug Recall by FDA

“Fresenius, the maker of GranuFlo and NaturaLyte, not only makes dialysis drugs, but it also provides dialysis services through dialysis centers located throughout the United States.” said Evans.

“The GranuFlo and NaturalLyte recall in 2012 was followed up by the filing of so many GranuFlo lawsuits that they were given multidistrict litigation status and transferred to the federal court in the District of Massachusetts on March 29, 2013,” Evans said.

Evans noted that “a June 17, 2013 report says that Bessemer Kidney Center, operated by Fresenius in Bessemer, Alabama, was closed in May 2013 after 2 deaths and 5 hospitalizations occurred within a few days. Although an investigation by the Alabama Department of Public Health did not find “a common thread” tying the deaths and hospitalizations together, the investigation did find “deficiencies” that must be addressed with a plan of action before the center can re-open, according to the report on The report says that “deficiencies” were found at the dialysis center last year, as well.”

The new website,, will focus on more than just GranuFlo and NaturaLyte lawsuits,” said Evans. “We plan to look at other potential cases for people who have been harmed by dialysis mistakes, defective dialysis equipment, or dialysis drugs such as GranuFlo or NaturaLyte.”

[Continue reading…]

Actos lawsuit says actos bladder cancer link revealed by testing on rats.

Actos lawsuit filed by whistleblower alleges deliberate coverup of Actos side effects.

Actos lawsuit filed by whistleblower recently unsealed by federal court: A whistleblower who filed an actos lawsuit against the maker o

f Actos makes serious allegations about a coverup of the Actos bladder cancer link. (Download a copy of the 111-page Actos lawsuit here). The actos lawsuit was filed by whistleblower Helen Ge, who is a medical doctor and former safety consultant to Takeda Pharmaceuticals.

Dr. Helen Ge’s Actos lawsuit involves Takeda’s failure to report bladder cancer, Congestive Heart Failure (CHF) and other adverse events

for the diabetes drug Actos. In her lawsuit, Dr. Ge alleges shocking misconduct, including these allegations about the Actos bladder cancer risk:

Dr. Ge had direct knowledge of the Actos bladder cancer risk and encountered resistance from her superiors when she tried to report bladder cancer as related to Actos. Dr. Ge claims her supervisors directed her to change her “related” assessment to unrelated. According to her recollection of reviewing Takeda’s adverse event database for Actos, there were more than 100 bladder cancers reported to the company, but only 72 reported to the FDA, which she alleges is a serious discrepancy. Dr. Ge also alleges that carcinogenesis from Actos was discovered during the initial Actos animal studies.

Actos attorneys who have filed Actos lawsuits for people with bladder cancer are taking a long look at Dr.

Ge’s lawsuit. If the allegations of the lawsuit are true, Actos’ manufacturer could be facing substantial compensatory and punitive damages in each bladder cancer victim’s actos lawsuit. A jury would be understandably upset if these allegations are proven:

  • That Dr. Ge’s supervisors ordered her to falsely report that side effects related to Actos were “unrelated.”
  • That the link between Actos

    and bladder cancer was shown as early as animal studies, before Actos was ever placed on the market.

  • That there were more than 100 Actos bladder cancer cases, but Takeda Pharmaceuticals reported only 72 of them to the FDA.

(Download a copy of the 111-page Actos lawsuit here).